Status and application of organoid technology in breast cancer research

doi:10.11958/20231745

Abstract

Abstract:

Organoids can well simulate the heterogeneity of tumors, including tumor microenvironment and immune response, which helps to more accurately predict patient responses to drug and treatment effects. Organoids can be used for drug screening before drugs enter body, thus reducing the time and cost of clinical trials. However, research on tissue-organoids still faces some challenges, such as technical limitation and ethical issue. This review mainly introduces the progress in the research of breast cancer organoids, including the definition of organoids, development history, advantages and application in breast cancer research.

Key words: organoids, breast neoplasms, drug screening assays, personalized medicine

CLC Number:

R655.8

References 30

[1]	SIEGEL R L, MILLER K D, FUCHS H E, et al. Cancer statistics,2022[J]. CA Cancer J Clin, 2022, 72(1):7-33. doi:10.3322/caac.21708.
[2]	GREENWALT I, ZAZA N, DAS S, et al. Precision medicine and targeted therapies in breast cancer[J]. Surg Oncol Clin N Am, 2020, 29(1):51-62. doi:10.1016/j.soc.2019.08.004.
[3]	LANCASTER M A, KNOBLICH J A. Organogenesis in a dish: modeling development and disease using organoid technologies[J]. Science, 2014, 345(6194):1247125. doi:10.1126/science.1247125.
[4]	SATO T, STANGE D E, FERRANTE M, et al. Long-term expansion of epithelial organoids from human colon,adenoma,adenocarcinoma,and Barrett's epithelium[J]. Gastroenterology, 2011, 141(5):1762-1772. doi:10.1053/j.gastro.2011.07.050.
[5]	SATO T, CLEVERS H. SnapShot: growing organoids from stem cells[J]. Cell, 2015, 161(7):1700-1700.e1. doi:10.1016/j.cell.2015.06.028.
[6]	YANG B, WEI K, LOEBEL C, et al. Enhanced mechanosensing of cells in synthetic 3D matrix with controlled biophysical dynamics[J]. Nat Commun, 2021, 12(1):3514. doi:10.1038/s41467-021-23120-0.
[7]	WANG F, WEAVER V M, PETERSEN O W, et al. Reciprocal interactions between beta1-integrin and epidermal growth factor receptor in three-dimensional basement membrane breast cultures: a different perspective in epithelial biology[J]. Proc Natl Acad Sci U S A, 1998, 95(25):14821-14826. doi:10.1073/pnas.95.25.14821.
[8]	JESPERSEN H, LINDBERG M F, DONIA M, et al. Clinical responses to adoptive T-cell transfer can be modeled in an autologous immune-humanized mouse model[J]. Nat Commun, 2017, 8(1):707. doi:10.1038/s41467-017-00786-z.
[9]	ZHAO Y, SHUEN T, TOH T B, et al. Development of a new patient-derived xenograft humanised mouse model to study human-specific tumour microenvironment and immunotherapy[J]. Gut, 2018, 67(10):1845-1854. doi:10.1136/gutjnl-2017-315201.
[10]	DIVOUX J, FLORENT R, JACOBS M, et al. The TRIPLEX study: use of patient-derived tumor organoids as an innovative tool for precision medicine in triple-negative breast cancer[J]. BMC Cancer, 2023, 23(1):883. doi:10.1186/s12885-023-11362-8.
[11]	SACHS N, DE LIGT J, KOPPER O, et al. A living biobank of breast cancer organoids captures disease heterogeneity[J]. Cell, 2018, 172(1/2):373-386. doi:10.1016/j.cell.2017.11.010.
[12]	PRINCE E, CRUICKSHANK J, BA-ALAWI W, et al. Biomimetic hydrogel supports initiation and growth of patient-derived breast tumor organoids[J]. Nat Commun, 2022, 13(1):1466. doi:10.1038/s41467-022-28788-6.
[13]	HOGSTROM J M, CRUZ K A, SELFORS L M, et al. Simultaneous isolation of hormone receptor-positive breast cancer organoids and fibroblasts reveals stroma-mediated resistance mechanisms[J]. J Biol Chem, 2023, 299(8):105021. doi:10.1016/j.jbc.2023.105021.
[14]	DEKKERS J F, WHITTLE J R, VAILLANT F, et al. Modeling breast cancer using CRISPR-Cas9-Mediated engineering of human breast organoids[J]. J Natl Cancer Inst, 2020, 112(5):540-544. doi:10.1093/jnci/djz196.
[15]	CHEW N J, LIM KAM SIAN T, NGUYEN E V, et al. Evaluation of FGFR targeting in breast cancer through interrogation of patient-derived models[J]. Breast Cancer Res, 2021, 23(1):82. doi:10.1186/s13058-021-01461-4.
[16]	VANDERVORST K, DREYER C A, HATAKEYAMA J, et al. Vangl-dependent Wnt/planar cell polarity signaling mediates collective breast carcinoma motility and distant metastasis[J]. Breast Cancer Res, 2023, 25(1):52. doi:10.1186/s13058-023-01651-2.
[17]	CAMPANER E, ZANNINI A, SANTORSOLA M, et al. Breast cancer organoids model patient-specific response to drug treatment[J]. Cancers (Basel), 2020, 12(12):3869. doi:10.3390/cancers12123869.
[18]	GUILLEN K P, FUJITA M, BUTTERFIELD A J, et al. A human breast cancer-derived xenograft and organoid platform for drug discovery and precision oncology[J]. Nat Cancer, 2022, 3(2):232-250. doi:10.1038/s43018-022-00337-6.
[19]	JIANG T, ZHU J, JIANG S, et al. Targeting lncRNA DDIT4-AS1 sensitizes triple negative breast cancer to chemotherapy via suppressing of autophagy[J]. Adv Sci (Weinh), 2023, 10(17):e2207257. doi:10.1002/advs.202207257.
[20]	SOOSAINATHAN A, IRAVANI M, EL-BOTTY R, et al. Targeting transcriptional regulation with a CDK9 inhibitor suppresses growth of endocrine- and palbociclib-resistant ER+ breast cancers[J]. Cancer Res, 2024, 84(1):17-25. doi:10.1158/0008-5472.CAN-23-0650.
[21]	SAEKI S, KUMEGAWA K, TAKAHASHI Y, et al. Transcriptomic intratumor heterogeneity of breast cancer patient-derived organoids may reflect the unique biological features of the tumor of origin[J]. Breast Cancer Res, 2023, 25(1):21. doi:10.1186/s13058-023-01617-4.
[22]	YANG L, LIU B, CHEN H, et al. Progress in the application of organoids to breast cancer research[J]. J Cell Mol Med, 2020, 24(10):5420-5427. doi:10.1111/jcmm.15216.
[23]	ZHOU Z, CONG L, CONG X. Patient-derived organoids in precision medicine: drug screening,Organoid-on-a-Chip and living Organoid Biobank[J]. Front Oncol, 2021, 11:762184. doi:10.3389/fonc.2021.762184.
[24]	SHU D, SHEN M, LI K, et al. Organoids from patient biopsy samples can predict the response of BC patients to neoadjuvant chemotherapy[J]. Ann Med, 2022, 54(1):2581-2597. doi:10.1080/07853890.2022.2122550.
[25]	DONG S, MATOSSIAN M D, YOUSEFI H, et al. Targeting Mcl-1 by a small molecule NSC260594 for triple-negative breast cancer therapy[J]. Sci Rep, 2023, 13(1):11843. doi:10.1038/s41598-023-37058-4.
[26]	YANG M, GUAN T, CHEN C F, et al. Mesothelin-targeted CAR-NK cells derived from induced pluripotent stem cells have a high efficacy in killing triple-negative breast cancer cells as shown in several preclinical models[J]. J Immunother, 2023, 46(8):285-294. doi:10.1097/CJI.0000000000000483.
[27]	SONG R, MA S, XU J, et al. A novel polypeptide encoded by the circular RNA ZKSCAN1 suppresses HCC via degradation of mTOR[J]. Mol Cancer, 2023, 22(1):16. doi:10.1186/s12943-023-01719-9.
[28]	NARAYAN P, PROWELL T M, GAO J J, et al. FDA approval summary:Alpelisib plus fulvestrant for patients with HR-positive, HER2-negative, PIK3CA-mutated, advanced or metastatic breast cancer[J]. Clin Cancer Res, 2021, 27(7):1842-1849. doi:10.1158/1078-0432.CCR-20-3652.
[29]	YANG Y S, JIN X, LI Q, et al. Superenhancer drives a tumor-specific splicing variant of MARCO to promote triple-negative breast cancer progression[J]. Proc Natl Acad Sci U S A, 2022, 119(46):e2207201119. doi:10.1073/pnas.2207201119.
[30]	TSAI K K, HUANG S S, NORTHEY J J, et al. Screening of organoids derived from patients with breast cancer implicates the repressor NCOR2 in cytotoxic stress response and antitumor immunity[J]. Nat Cancer, 2022, 3(6):734-752. doi:10.1038/s43018-022-00375-0.